Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.66 |
| ▸ | GAA | P10253 | 5/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | NCF1 | P14598 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3971486 | 0.99 | KMT2A (0.65) | KMT2AKDM4EGAAL3MBTL1ACHE | |
| SCHEMBL3971612 | 0.84 | EGFR (0.51) | KMT2AKDM4EGAAL3MBTL1ACHE | |
| SCHEMBL3965636 | 0.83 | HRH3 (0.58) | KMT2AKDM4EGAAL3MBTL1ACHE | |
| Hydrochloric Acid SCHEMBL3972947 | 0.83 | EGFR (0.50) | KMT2AKDM4EGAAL3MBTL1ACHE | |
| SCHEMBL5910684 | 0.82 | KMT2A (0.72) | KMT2AKDM4EGAAL3MBTL1ACHE | |
| Hydrochloric Acid SCHEMBL3977169 | 0.82 | HRH3 (0.57) | KMT2AKDM4EGAAL3MBTL1ACHE | |
| SCHEMBL5910282 | 0.80 | KMT2A (1.00) | KMT2AKDM4EGAAL3MBTL1ACHE | |
| SCHEMBL6509689 | 0.80 | KMT2A (0.78) | KMT2AKDM4EGAAL3MBTL1ACHE | |
| SCHEMBL26723750 | 0.80 | KDM4E (1.00) | KMT2AKDM4EGAAL3MBTL1ACHE | |
| SCHEMBL14975993 | 0.79 | KDM4E (1.00) | KMT2AKDM4EGAAL3MBTL1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| EP-1474401-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| WO-2003066604-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | KMT2A 301/4885KDM4E 1574/4885GAA 2437/4885 |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HRH3, HRH2, HRH4 | KMT2A 301/4885KDM4E 1574/4885GAA 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.